Witkowski, Matthew T.
Lee, Soobeom
Wang, Eric
Lee, Anna K.
Talbot, Alexis http://orcid.org/0000-0001-6734-413X
Ma, Chao
Tsopoulidis, Nikolaos
Brumbaugh, Justin
Zhao, Yaqi http://orcid.org/0000-0002-8230-5312
Roberts, Kathryn G.
Hogg, Simon J. http://orcid.org/0000-0002-3170-839X
Nomikou, Sofia
Ghebrechristos, Yohana E.
Thandapani, Palaniraja http://orcid.org/0000-0002-9881-3645
Mullighan, Charles G. http://orcid.org/0000-0002-1871-1850
Hochedlinger, Konrad http://orcid.org/0000-0001-5811-5386
Chen, Weiqiang http://orcid.org/0000-0002-9469-8328
Abdel-Wahab, Omar http://orcid.org/0000-0002-3907-6171
Eyquem, Justin http://orcid.org/0000-0001-8262-1190
Aifantis, Iannis http://orcid.org/0000-0001-6857-1035
Funding for this research was provided by:
U.S. Department of Health; Human Services | NIH | National Cancer Institute (RO1CA252239, R01CA228135, R01CA242020, RO1CA266212, 1K22CA258520-01, 1P50 254838-01, CA197695)
Leukemia and Lymphoma Society (5468-18)
Curing Kids Cancer Vogelstein Foundation
Cancer League of Colorado (AWD#222549)
American Society of Hematology
The Jeffrey Pride Foundation for Pediatric Cancer Research and the Children’s Oncology Group Foundation
Parker Institute for Cancer immunotherapy and the Grand Multiple Myeloma Translational Initiative
Deutsche Forschungsgemeinschaft
U.S. Department of Health; Human Services | National Institutes of Health (1F32HD078029-01A1, P01 GM099134, R01 CA251138, R01 CA242020, R35GM133646)
National Health and Medical Research Council (NHMRC) of Australia
Alexander S. Onassis Public Benefit Foundation (F ZP 036-1/2019-2020)
American Association for Cancer Research
Alex’s Lemonade Stand Foundation for Childhood Cancer
Gerald and Darlene Jordan Chair in Regenerative Medicine
Edward P. Evans Foundation
Cancer Research Institute (CRI4018)
American Lebanese Syrian Associated Charities
Henry Schueler 41&9 Foundation
National Science Foundation (CBET 2103219)
Article History
Received: 5 January 2022
Accepted: 11 August 2022
First Online: 22 September 2022
Competing interests
: I.A. is a consultant for Foresite Labs and receives research funding from AstraZeneca. A.T. is a scientific advisor to Intelligencia AI. M.T.W has received royalties from the Walter and Eliza Hall Institute for the development of venetoclax unrelated to the current manuscript. O.A.-W. has served as a consultant for H3B Biomedicine, Foundation Medicine Inc., Merck, Prelude Therapeutics and Janssen and is on the Scientific Advisory Board of Envisagenics Inc., AIChemy, Harmonic Discovery Inc. and Pfizer Boulder. He has received previous research funding from H3B Biomedicine and LOXO Oncology unrelated to the current manuscript. C.G.M. receives research support from AbbVie and Pfizer, is a member of the advisory boards of Faze, Beam and Illumina and has accepted speaking fees from Amgen. J.E. is a compensated co-founder at Mnemo Therapeutics and a compensated scientific advisor to Cytovia Therapeutics, owns stocks in Mnemo Therapeutic and Cytovia Therapeutics and has received a consulting fee from Casdin Capital. He is also a holder of patents pertaining to but not resulting from this work. J.E.’s lab has received research support from Cytovia Therapeutic, Mnemo Therapeutics and Takeda. The remaining authors declare no competing interests.